- Health Conditions
- Events
- MedWire
- Ask a Doctor
- Visit A Doctor
- Medimorphosis
- HCP Portal
Subscribe to Updates
Get the latest creative news from FooBar about art, design and business.
Browsing: Lecanemab
USC scientists have created a 5-in-1 blood test to detect Alzheimer’s in its earliest stages. Could this be the future of routine dementia screening?
A novel Alzheimer’s disease treatment drug, lecanemab, developed by Japanese pharmaceutical company Eisai and US firm Biogen, is nearing full approval in the US. Excitement is also building in Japan where the population of Alzheimer’s patients is growing and Prime Minister Fumio Kishida has prioritised dementia. The drug is undergoing an expedited review by the Japanese Pharmaceuticals and Medical Devices Agency and could potentially be approved this autumn.
Lecanemab is one of the first experimental drugs for dementia which appears to help in slowing down the progression of cognitive decline.
Subscribe to Updates
Subscribe to receive latest health related news from us
The contents on Medical Channel Asia are for general educational purposes only.
It is not intended to be a substitute for professional medical advice, treatment, or diagnosis.
See additional information.